CRISPR (CRSP) CMO Naimish Patel Sells 3,150 Shares

What Happened
Naimish Patel, Chief Medical Officer of CRISPR Therapeutics (CRSP), had 8,125 restricted stock units convert/vest on March 14, 2026 (reported as a derivative exercise/conversion). Following the vesting, Patel sold 3,150 shares in an open-market sale on March 16, 2026 at $48.26 per share, receiving $152,019. The sale was done to satisfy tax withholding tied to the RSU vesting and was mandated by the company's RSU Settlement Policy (not a discretionary trade).

Key Details

• Transactions reported:
  • 2026-03-14: Conversion/exercise of derivative (RSU vesting) — 8,125 shares (no cash price; conversion event).
  • 2026-03-16: Open-market sale — 3,150 shares @ $48.26 = $152,019.
  • 2026-03-14: A derivative disposition of 8,125 shares is also reported (reflecting the conversion/settlement mechanics).
• Shares owned after transaction: Not specified in the filing.
• Relevant footnotes:
  • F4: The 3,150-share sale represents shares sold to cover tax withholding for the RSU vesting and was required by company policy (not a discretionary sale).
  • F5: The RSU award (32,500 shares) was granted 3/14/2025 with quarterly vesting; 8,125 shares vested 3/14/2026.
  • F1: Some shares remain subject to a lock-up agreement with the underwriters of the issuer’s convertible senior notes offering.
  • F2/F3: RSUs convert to one common share each; the reporting includes 592 shares from the employee stock purchase plan.
• Filing date / timeliness: Form 4 filed 2026-03-17 covering the 3/14–3/16 activity; no late-filing flag was indicated.

Context

• The March 14 entry is a vesting/conversion of RSUs (transaction code M for exercise/conversion of a derivative). A portion of the vested shares was sold shortly after to cover taxes—this is a routine, non-discretionary settlement-related sale rather than a voluntary sell signal from the insider.
• For retail investors, mandatory withholding sales tied to RSU vesting are common and generally less informative about insider sentiment than voluntary open-market purchases.